8-K: Context Therapeutics Reports Positive CTIM-76 Phase 1 Data

Context Therapeutics announces encouraging interim Phase 1 data for CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, showing a 29% ORR in platinum-resistant ovarian cancer.

Summary

• Context Therapeutics Inc. has released positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, an investigational Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody.
• The data, as of May 29, 2026, from the CTIM-76-101 study (NCT06515713) in advanced, late-line platinum-resistant ovarian cancer (PROC) patients, showed a 29% confirmed overall response rate (ORR) per RECIST v1.1.
• In PROC patients who progressed on a median of 7 prior lines of therapy, the disease control rate (DCR) was 57%.
• Cytokine Release Syndrome (CRS) was infrequent and limited to Grade 1 in 11% of PROC patients at active dose levels, suggesting potential for outpatient dosing.
• The pharmacokinetic profile supports the exploration of a Q3W (every three weeks) dosing schedule, with updated data expected in Q4 2026 and Q3W dosing data in Q2 2027.
• CTIM-76 has received FDA Fast Track Designation for PROC.
• The company plans to host a conference call on June 15, 2026, to discuss these interim results.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with encouraging clinical data and FDA Fast Track Designation for CTIM-76, suggesting strong potential for the drug candidate.

Positives

• Achieved a 29% confirmed overall response rate (ORR) in platinum-resistant ovarian cancer (PROC) patients.
• Demonstrated a 57% disease control rate (DCR) in PROC patients.
• Observed a low rate of Cytokine Release Syndrome (CRS), limited to Grade 1 in 11% of PROC patients at active doses.
• The pharmacokinetic profile supports the evaluation of a Q3W dosing schedule, potentially improving patient convenience and durability.
• CTIM-76 has been granted FDA Fast Track Designation for PROC.
• The drug showed dose-proportional anti-tumor activity and tumor shrinkage across multiple lesions.
• Emerging durability signal observed, with potential for improvement with less frequent dosing.
• A significant market opportunity exists in CLDN6+ PROC patients with high unmet need.

Negatives

• The study population was heavily pre-treated, with a median of 7 prior lines of therapy.
• 560g dose exceeded target exposures with QW dosing and was not pursued further.
• While promising, the data is interim and subject to further analysis.
• The trial is ongoing, and further data is needed to confirm efficacy and safety.

Risks

• Uncertainties regarding the Company's expectations, projections, and estimates of future costs and expenses, capital requirements, and the availability of additional financing.
• The timing, progress, and results of clinical development activities, including potential unexpected safety or efficacy data.
• Risks associated with the regulatory approval process.
• Reliance on third parties for development and manufacturing.
• Macroeconomic conditions could impact the company's operations and funding.
• The risk that results from nonclinical or clinical studies may not be predictive of future results.
• Interim data is subject to further analysis and potential changes.

Future Outlook

The company expects updated QW data for CTIM-76 in Q4 2026 and Q3W dosing data in Q2 2027. Preliminary Phase 1a data for CT-95 is anticipated in September 2026, and Phase 1 FPI for CT-202 is expected in Q3 2026. The company has an expected cash runway into mid-2027.

Management Comments

• "We are encouraged by the continued development of CTIM-76 as a potentially best-in-class CLDN6 T cell engager that may offer a much-needed new therapeutic approach for patients with platinum-resistant ovarian cancer."
• "Building on this encouraging data, we have advanced into the next phase of development, where we will evaluate CTIM-76 administered every three weeks (Q3W)."
• "These results are expected to inform subsequent Phase 1b dose expansion in 2027."

Industry Context

StockSavvy.ai notes that the positive interim data for CTIM-76 aligns with the growing success and investment in T cell engaging (TCE) bispecific antibodies for solid tumors, a field seeing increasing FDA approvals and strong commercial launches.

Comparison to Industry Standards

• The ORR of 29% for CTIM-76 in heavily pre-treated PROC patients (median 7 prior lines of therapy) is competitive within this difficult-to-treat population, especially considering the low rate of CRS.
• Benchmarking CRS rates against approved TCEs like Talvey (GPCR5 x CD3), Elfrexio (BCMA x CD3), Epkinly (CD20 x CD3), and Imdelltra (DLL3 x CD3) shows CTIM-76's Grade 1 CRS rate of 11% is comparable or lower than some, indicating a potentially manageable safety profile.
• The company's pipeline of CT-95 (MSLN x CD3) and CT-202 (Nectin-4 x CD3) targets also align with other industry efforts to develop next-generation TCEs for various solid tumors.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial progress and potential drug candidate could lead to increased investor confidence and stock value.
• Patients: The positive results offer hope for a new therapeutic option for patients with platinum-resistant ovarian cancer, a population with significant unmet needs.
• Healthcare Providers: The data provides new information on the efficacy and safety of CTIM-76, which will inform treatment decisions for eligible patients.

Next Steps

• Evaluate CTIM-76 administered every three weeks (Q3W).
• Inform subsequent Phase 1b dose expansion in 2027.
• Continue Phase 1a dose escalation for CTIM-76.
• Anticipate updated QW data for CTIM-76 in Q4 2026.
• Anticipate Q3W dosing data for CTIM-76 in Q2 2027.
• Anticipate preliminary Phase 1a data for CT-95 in September 2026.
• Anticipate Phase 1 First Patient Dosed (FPI) for CT-202 in Q3 2026.

Key Dates

Recommendation

The interim Phase 1 data for CTIM-76 is encouraging, showing positive efficacy and a manageable safety profile, leading to FDA Fast Track Designation. However, it is still early-stage data from a small patient population. Further data from dose expansion and later-stage trials are needed to confirm these findings and assess the drug's full potential. Therefore, a 'hold' recommendation is appropriate pending more robust clinical evidence.

Keywords

CTIM-76, T cell engager, Claudin 6, bispecific antibody, platinum-resistant ovarian cancer, Phase 1 clinical trial, oncology, biotechnology